SRPT Earnings & Financial Statements
Sarepta Therapeutics, Inc.
$16.83
+$0.32(+1.94%)
50
Overall
60
Value
40
Tech
52
Quality
Market Cap
$1.78B
Volume
2.74M
52W Range
$14.68 - $24.68
Target Price
$21.35
SRPT earnings and financial statements: Sarepta Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
SRPT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $2.20B | $1.90B | $1.24B | $933.01M | $701.89M |
| Cost of revenue | $839.61M | $319.10M | $150.34M | $139.99M | - |
| Operating income | -$699.78M | $218.08M | -$267.82M | -$536.20M | -$459.71M |
| EBITDA | -$657.70M | $298.50M | -$475.70M | -$648.10M | -$217.55M |
| Net income | -$713.41M | $235.24M | -$535.98M | -$703.49M | -$418.78M |
| EPS (diluted) | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B |
| Total liabilities | $2.21B | $2.44B | $2.41B | $2.74B | $2.22B |
| Shareholders’ equity | $1.14B | $1.53B | $859.34M | $384.95M | $928.01M |
| Cash and equivalents | $801.30M | $1.10B | $428.43M | $966.78M | $2.12B |
| Long-term debt | $1.03B | $1.33B | $1.27B | $1.60B | $1.14B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$205.48M | -$205.79M | -$500.99M | -$325.35M | -$443.17M |
| Capital expenditure | -$109.85M | -$146.96M | -$87.34M | -$32.25M | -$40.80M |
| Free cash flow | -$315.33M | -$352.74M | -$588.34M | -$357.60M | -$483.97M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SRPT | $16.83 | +1.9% | 2.74M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Sarepta Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW